SANA (MVD1)

pharmacological · endocrine · Oral

SANA (MVD1). Investigational salicylate-derived nitroalkene studied in preclinical metabolic models and an early human clinical study.

Investigational salicylate-derived nitroalkene studied in preclinical metabolic models and an early human clinical study.

PK: PMID:40527924 includes early human work under the MVD1 designation; effects in animals must not be represented as established human efficacy. DOSE FULL TEXT: PMID:40527924 Methods and Extended Data Table 1 report oral SAD 200, 400 or 800 mg and MAD 100, 150 or 200 mg per dose every 12 h for 14 days plus a final morning dose on day 15. Reversible renal tubular effects occurred at the highest SAD. Quantitative human PK requires the supplement; mouse Tmax must not be transferred.

Sources: PMID:40527924